Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages

  Lambert, Sally R ^a,b   Harwood, Catherine A ^a,b   Purdie, Karin J ^a,b   Gulati, Abha ^a   Matin, Rubeta N ^a   Romanowska, Malgorzata ^c   Cerio, Rino ^a   Kelsell, David P ^a   Leigh, Irene M ^b,c   Proby, Charlotte M ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

5 untranslated region; cutaneous squamous cell carcinoma; metastasis; PTPRD

Indexed keywords

BIOLOGICAL MARKER; FORMALDEHYDE; PARAFFIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR D; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; EMBEDDING; GENE DELETION; GENE DISRUPTION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; METHYLATION; MICROARRAY ANALYSIS; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PTPRD GENE; SKIN CARCINOMA; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; TISSUE FIXATION;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; GENOTYPE; HUMANS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861578193     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27333     Document Type: Article

References (44)

1. Madan V, Hoban P, Strange RC, Fryer AA, Lear JT,. Genetics and risk factors for basal cell carcinoma. Br J Dermatol 2006; 154 (Suppl 1): 5-7.
2. Cancer Research UK (2009). Skin cancer statistics-UK [Online]. Available: http://info.cancerresearchuk.org/cancerstats/types/skin/?script=true. Date accessed: 2010
3. Euvrard S, Kanitakis J, Claudy A,. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91.
4. Lund HZ,. How often does squamous cell carcinoma of the skin metastasize? Arch Dermatol 1965; 92: 635-7.
5. Rowe DE, Carroll RJ, Day CL, Jr,. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-90.
6. Tavin E, Persky M,. Metastatic cutaneous squamous cell carcinoma of the head and neck region. Laryngoscope 1996; 106: 156-8.
7. Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, Breuninger H,. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-20.
8. Kraus DH, Carew JF, Harrison LB,. Regional lymph node metastasis from cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124: 582-7.
9. Tornaletti S, Rozek D, Pfeifer GP,. Mapping of UV photoproducts along the human P53 gene. Ann N Y Acad Sci 1994; 726: 324-6.
10. Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM,. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol 2004; 122: 1284-92.
11. Purdie KJ, Harwood CA, Gulati A, Chaplin T, Lambert SR, Cerio R, Kelly GP, Cazier JB, Young BD, Leigh IM, Proby CM,. Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol 2009; 129: 1562-8.
12. Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M, Kelsell DP, Leigh IM, Harwood CA, Proby CM, Young BD,. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer 2007; 46: 661-9.
13. Sato M, Takahashi K, Nagayama K, Arai Y, Ito N, Okada M, Minna JD, Yokota J, Kohno T,. Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer. Genes Chromosomes Cancer 2005; 44: 405-14.
14. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005; 65: 5561-70.
15. Stark M, Hayward N,. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007; 67: 2632-42.
16. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O'Meara A, Breatnach F,. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 2006; 66: 3673-80.
17. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T,. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 2008; 68: 10300-6.
18. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-Cespedes M, Minna JD, Yokota J,. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene. Genes Chromosomes Cancer 2010; 49: 342-52.
19. Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M, Szaumkessel M, Pelinska K, Kiwerska K, Tonnies H, Grenman R, Figlerowicz M, Siebert R, et al. High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. Genes Chromosomes Cancer 2011; 50: 154-66.
20. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB,. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008; 5: e114.
21. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 2009; 106: 9435-40.
22. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-8.
23. MacKeigan JP, Murphy LO, Blenis J,. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7: 591-600.
24. Proby CM, Purdie KJ, Sexton CJ, Purkis P, Navsaria HA, Stables JN, Leigh IM,. Spontaneous keratinocyte cell lines representing early and advanced stages of malignant transformation of the epidermis. Exp Dermatol 2000; 9: 104-17.
25. Fan JB, Gunderson KL, Bibikova M, Yeakley JM, Chen J, Wickham Garcia E, Lebruska LL, Laurent M, Shen R, Barker D,. Illumina universal bead arrays. Methods Enzymol 2006; 410: 57-73.
26. Howarth K, Ranta S, Winter E, Teixeira A, Schaschl H, Harvey JJ, Rowan A, Jones A, Spain S, Clark S, Guenther T, Stewart A, et al. A mitotic recombination map proximal to the APC locus on chromosome 5q and assessment of influences on colorectal cancer risk. BMC Med Genet 2009; 10: 54.
27. Assie G, LaFramboise T, Platzer P, Bertherat J, Stratakis CA, Eng C,. SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet 2008; 82: 903-15.
28. Lee S, Syed N, Taylor J, Smith P, Griffin B, Baens M, Bai M, Bourantas K, Stebbing J, Naresh K, Nelson M, Tuthill M, et al. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma. Br J Cancer 2010; 103: 265-74.
29. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
30. Nair P, De Preter K, Vandesompele J, Speleman F, Stallings RL,. Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas. Genes Chromosomes Cancer 2008; 47: 197-202.
31. Tonks NK,. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 7: 833-46.
32. Trapasso F, Yendamuri S, Dumon KR, Iuliano R, Cesari R, Feig B, Seto R, Infante L, Ishii H, Vecchione A, During MJ, Croce CM, et al. Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. Carcinogenesis 2004; 25: 2107-14.
33. Xu Y, Tan LJ, Grachtchouk V, Voorhees JJ, Fisher GJ,. Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. J Biol Chem 2005; 280: 42694-700.
34. Flavell JR, Baumforth KR, Wood VH, Davies GL, Wei W, Reynolds GM, Morgan S, Boyce A, Kelly GL, Young LS, Murray PG,. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008; 111: 292-301.
35. Cheung AK, Lung HL, Hung SC, Law EW, Cheng Y, Yau WL, Bangarusamy DK, Miller LD, Liu ET, Shao JY, Kou CW, Chua D, et al. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res 2008; 68: 8137-45.
36. Zheng XM, Wang Y, Pallen CJ,. Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature 1992; 359: 336-9.
37. Berndt A, Luo X, Bohmer FD, Kosmehl H,. Expression of the transmembrane protein tyrosine phosphatase RPTPalpha in human oral squamous cell carcinoma. Histochem Cell Biol 1999; 111: 399-403.
38. Wu CW, Kao HL, Li AF, Chi CW, Lin WC,. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Lett 2006; 242: 95-103.
39. Chen SY, Takeuchi S, Moroi Y, Hayashida S, Kido M, Chen SJ, Tomoeda H, Uenotsuchi T, Tu YT, Furue M, Urabe K,. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous squamous cell carcinoma, Bowen's disease and basal cell carcinoma. J Dermatol Sci 2008; 51: 210-15.
40. Bito T, Sumita N, Ashida M, Budiyanto A, Ueda M, Ichihashi M, Tokura Y, Nishigori C,. Inhibition of epidermal growth factor receptor and PI3K/Akt signaling suppresses cell proliferation and survival through regulation of Stat3 activation in human cutaneous squamous cell carcinoma. J Skin Cancer 2011; 2011: 874571.
41. Pesole G, Mignone F, Gissi C, Grillo G, Licciulli F, Liuni S,. Structural and functional features of eukaryotic mRNA untranslated regions. Gene 2001; 276: 73-81.
42. Vartanian JG, Carvalho AL, de Araujo Filho MJ, Junior MH, Magrin J, Kowalski LP,. Predictive factors and distribution of lymph node metastasis in lip cancer patients and their implications on the treatment of the neck. Oral Oncol 2004; 40: 223-7.
43. Fogarty GB, Conus NM, Chu J, McArthur G,. Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 2007; 156: 92-8.
44. Harwood CA, Proby CM, McGregor JM, Sheaff MT, Leigh IM, Cerio R,. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. J Am Acad Dermatol 2006; 54: 290-300.